Overview
- Lilly agreed to buy AtaiBeckley for up to $3.8 billion with about $2.8 billion paid upfront, and the boards approved a transaction expected to close in the third quarter pending shareholder and regulatory approvals.
- AtaiBeckley’s lead drug, BPL‑003 (a synthetic intranasal form of 5‑MeO‑DMT), holds FDA Breakthrough Therapy designation and has advanced into Phase III testing as a treatment for treatment‑resistant depression.
- Recent regulatory moves, including a presidential executive order and the FDA’s July guidance on psychedelic trials, have shortened some procedural barriers for study and review of these drugs.
- Analysts raised peak‑sales forecasts for BPL‑003 to multibillion‑dollar levels and markets reacted positively to the deal, with AtaiBeckley shares jumping and Lilly shares edging up after the announcement.
- Key unresolved questions that will determine patient access are the Phase III outcomes, FDA approval timing, DEA rescheduling for 5‑MeO‑DMT, and whether insurers will cover clinic‑based, one‑day psychedelic treatments.